AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19690792 — intervention group
Group type: COMPARATOR
Intervention: Individual pelvic floor muscle training (PFMT)
Number of subjects: 60
Study 19690792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both group and individual PFMT
Number of subjects: 60
Study 16893694 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9 drug-eluting stent
Number of subjects: 120
Study 16893694 — intervention group
Group type: COMPARATOR
Intervention: Control uncoated stent
Number of subjects: 120
Study 15082989 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall opioid use
Number of subjects: 0
Study 15082989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone or hydrocodone
Number of subjects: 0
Study 15082989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene
Number of subjects: 0
Study 15082989 — intervention group
Group type: COMPARATOR
Intervention: Health insurance status and geographic regions
Number of subjects: 0
Study 11748361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid samples from patients with aneurysmal SAH
Number of subjects: 19
Study 9290452 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of misoprostol
Number of subjects: 399
Study 9290452 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of misoprostol
Number of subjects: 399
Study 8222513 — intervention group
Group type: COMPARATOR
Intervention: D-glucose infusion
Number of subjects: 6
Study 8222513 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion
Number of subjects: 6
Study 3951807 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose Amicar (50 mg/kg every four hours for five days, up to a maximum of 30 g/day)
Number of subjects: 59
Study 3951807 — intervention group
Group type: COMPARATOR
Intervention: Full-dose Amicar (100 mg/kg every four hours, up to a maximum of 30 g/day)
Number of subjects: 59
Study 3951807 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Half-dose and Full-dose)
Number of subjects: 59
Study 3951807 — intervention group
Group type: COMPARATOR
Intervention: Both dose levels of Amicar
Number of subjects: 59
Study 3951807 — intervention group
Group type: COMPARATOR
Intervention: Prior aspirin ingestion
Number of subjects: 59
Study 29557487 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (Transcutaneous Electrical Acupoint Stimulation)
Number of subjects: 120
Study 29557487 — intervention group
Group type: COMPARATOR
Intervention: Control (Tramadol hydrochloride tablets)
Number of subjects: 120
Study 29750367 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (2 g daily)
Number of subjects: 69
Study 29750367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 25649051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg OPC
Number of subjects: 40
Study 25649051 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg OPC
Number of subjects: 40
Study 25649051 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg OPC
Number of subjects: 40
Study 25649051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25012176 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA/heparin (1 mg per lumen, once per week)
Number of subjects: 0
Study 25012176 — intervention group
Group type: COMPARATOR
Intervention: heparin alone (thrice-weekly)
Number of subjects: 0
Study 25012176 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA/heparin
Number of subjects: 0
Study 22654433 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive gastric cancer patients with liver metastases
Number of subjects: 84
Study 22654433 — intervention group
Group type: COMPARATOR
Intervention: HER2 negative gastric cancer patients with liver metastases
Number of subjects: 84
Study 19523170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudocatalase cream with NB‐UVB
Number of subjects: 32
Study 19523170 — intervention group
Group type: COMPARATOR
Intervention: Placebo with NB‐UVB
Number of subjects: 32
Study 17035933 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous paroxetine treatment
Number of subjects: 56
Study 17035933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent paroxetine treatment (luteal phase only)
Number of subjects: 56
Study 17035933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16304269 — intervention group
Group type: EXPERIMENTAL
Intervention: IV azithromycin plus IV ceftriaxone followed by oral azithromycin
Number of subjects: 163
Study 16304269 — intervention group
Group type: COMPARATOR
Intervention: IV levofloxacin followed by oral levofloxacin
Number of subjects: 163
Study 11986110 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.0015%
Number of subjects: 605
Study 11986110 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 605
Study 11986110 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 605
Study 9607375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 50
Study 9607375 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 50
Study 7612039 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 106
Study 7612039 — intervention group
Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 106
Study 7612039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroids
Number of subjects: 106
Study 7612039 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RA group
Number of subjects: 106
Study 1643914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-release albuterol sulfate (8 mg)
Number of subjects: 10
Study 1643914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6383749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 2.4 mg/kg at 12‐ or 18‐hour dosing intervals
Number of subjects: 22
Study 31037845 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation within four weeks
Number of subjects: 701
Study 31037845 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP retention at four weeks
Number of subjects: 701
Study 31037845 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to clinic ≥2 km
Number of subjects: 701
Study 31037845 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility during home-based testing without same-day PrEP start
Number of subjects: 701
Study 31037845 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to PrEP use
Number of subjects: 701
Study 29374469 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (4-6 mg/kg/h)
Number of subjects: 54
Study 29374469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil (approx. 2.2 vol% endtidal)
Number of subjects: 54
Study 27310330 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC299 (0.03 to 3 mg/kg single dose)
Number of subjects: 0
Study 27310330 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC299 (0.3 to 1.2 mg/kg twice a day or 1.6 mg/kg 3 times a day for 7 days)
Number of subjects: 0
Study 25623098 — intervention group
Group type: EXPERIMENTAL
Intervention: R3 thoracic sympathicotomy
Number of subjects: 200
Study 25623098 — intervention group
Group type: COMPARATOR
Intervention: R3 thoracic sympathicotomy plus bypass fiber resection (R3+)
Number of subjects: 200
Study 22404324 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (therapeutic dose 750 mg)
Number of subjects: 16
Study 22404324 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (low dose 7.5 mg)
Number of subjects: 16
Study 22404324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (therapeutic dose 200 mg)
Number of subjects: 16
Study 22404324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (low dose 2 mg)
Number of subjects: 16
Study 19961902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24
Study 19961902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18675294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive perception information curriculum
Number of subjects: 2734
Study 18675294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive perception information + behavioral skills curriculum
Number of subjects: 2734
Study 18675294 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2734
Study 18675294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive perception information curriculum and Cognitive perception information + behavioral skills curriculum
Number of subjects: 2734
Study 16192259 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements
Number of subjects: 92
Study 16192259 — intervention group
Group type: COMPARATOR
Intervention: Orlistat
Number of subjects: 92
Study 12856809 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Nylestriol Tablet (CNT) - 0.5 mg nylestriol and 0.15 mg levonorgestrel, one tablet per week for one year
Number of subjects: 191
Study 12856809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 10941861 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 43
Study 10941861 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative techniques
Number of subjects: 43
Study 10941861 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo needle application)
Number of subjects: 43
Study 7851278 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (high-dose, 3 day regimen)
Number of subjects: 25
Study 7851278 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (standard 5-day course)
Number of subjects: 25
Study 7851278 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 25
Study 7851278 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 25
Study 2682412 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of 10 mg meperidine every 20 minutes
Number of subjects: 64
Study 2682412 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered meperidine (25-50 mg every 3 hours as requested)
Number of subjects: 64
Study 2682412 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of meperidine
Number of subjects: 64
Study 338400 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg daily of maprotiline (Ludiomil) administered once or thrice daily
Number of subjects: 191
Study 338400 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg daily of maprotiline (Ludiomil) administered once or thrice daily
Number of subjects: 191
Study 338400 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg three times daily of maprotiline (Ludiomil)
Number of subjects: 191
Study 338400 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg thrice daily of maprotiline (Ludiomil)
Number of subjects: 191
Study 338400 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nocte of maprotiline (Ludiomil)
Number of subjects: 191
Study 31915160 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lithium carbonate
Number of subjects: 160
Study 31915160 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 160
Study 30930360 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scoring model based on predictors associated with mortality (anemia, tuberculous meningitis, severe pneumonia, hypoalbuminemia, unexplained infections or space‐occupying lesions, malignancies)
Number of subjects: 1007
Study 30930360 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scoring model categorized into low-risk (0-2 points) and high-risk (4-16 points) groups
Number of subjects: 1007
Study 30930360 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curve analysis
Number of subjects: 1007
Study 28366730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 166
Study 28366730 — intervention group
Group type: COMPARATOR
Intervention: Loop electrosurgical excision procedure
Number of subjects: 166
Study 25855884 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant administration
Number of subjects: 317
Study 25855884 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 317
Study 23765945 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (folic acid, 2 mg; vitamin B6, 25 mg; vitamin B12, 500 μg)
Number of subjects: 8164
Study 23765945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8164
Study 23765945 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins
Number of subjects: 8164
Study 21147261 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin continuation
Number of subjects: 100
Study 21147261 — intervention group
Group type: COMPARATOR
Intervention: Warfarin interruption
Number of subjects: 100
Study 18678567 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pursed lips breathing
Number of subjects: 32
Study 18678567 — intervention group
Group type: COMPARATOR
Intervention: Prevented spontaneous pursed lips breathing (using a mouthpiece)
Number of subjects: 32
Study 17202604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (20 percent)
Number of subjects: 104
Study 17202604 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐nutritive sucking (NNS)
Number of subjects: 104
Study 17202604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking
Number of subjects: 104
Study 17202604 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 104
Study 17202604 — intervention group
Group type: COMPARATOR
Intervention: Expressed breast milk (EBM)
Number of subjects: 104
Study 17202604 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 104
Study 12744410 — intervention group
Group type: EXPERIMENTAL
Intervention: PMRC/RC open sandwich restoration
Number of subjects: 57
Study 12744410 — intervention group
Group type: COMPARATOR
Intervention: RC control restoration
Number of subjects: 57
Study 10948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat blind (RFB)
Number of subjects: 279
Study 10948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat informed (RFI)
Number of subjects: 279
Study 10948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat informed with details (RFID)
Number of subjects: 279
Study 10948387 — intervention group
Group type: COMPARATOR
Intervention: Full-fat blind (FFB)
Number of subjects: 279
Study 8832308 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (4 micrograms/kg body weight)
Number of subjects: 20
Study 8832308 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (3 micrograms/kg body weight)
Number of subjects: 20
Study 8174496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g q 8 h i.v.)
Number of subjects: 496
Study 8174496 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g single dose)
Number of subjects: 496
Study 3804901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 48
Study 3804901 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 48
Study 28576557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (ELT)
Number of subjects: 38
Study 28576557 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with saline heparin locks (Control)
Number of subjects: 38
Study 27423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (12 week, three times per week progressive exercise program including aerobic and strengthening exercises)
Number of subjects: 32
Study 27423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 32
Study 27423921 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 32
Study 24470182 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich supplementation
Number of subjects: 0
Study 24470182 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich supplementation
Number of subjects: 0
Study 22320849 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline oral health-related knowledge, attitudes, and beliefs regarding caries control.
Number of subjects: 493
Study 22320849 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about getting decay in one's own teeth.
Number of subjects: 493
Study 22320849 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about mother's cavities.
Number of subjects: 493
Study 19474006 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 34
Study 19474006 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 34
Study 19474006 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulative therapy
Number of subjects: 34
Study 18302125 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-directed program (T-D)
Number of subjects: 44
Study 18302125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program (T-D + CAI)
Number of subjects: 44
Study 18302125 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional (CAI) program
Number of subjects: 44
Study 18302125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cognitive strategies training)
Number of subjects: 44
Study 15996346 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy Guard (topical cream containing zinc gel)
Number of subjects: 0
Study 11812552 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 31402
Study 10343146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1,000 mg b.i.d. for 7 days
Number of subjects: 61
Study 8613276 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education classes (4 classes in the first 6 months and 4 classes in the next year)
Number of subjects: 111
Study 8613276 — intervention group
Group type: COMPARATOR
Intervention: Community-based education classes (2 classes)
Number of subjects: 111
Study 8613276 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education classes
Number of subjects: 111
Study 1894479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioptic stimuli (identical to both eyes)
Number of subjects: 0
Study 1894479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic stimuli (differed between the two eyes)
Number of subjects: 0
Study 1894479 — intervention group
Group type: COMPARATOR
Intervention: Random variations in display contrast
Number of subjects: 0
Study 6807149 — intervention group
Group type: EXPERIMENTAL
Intervention: DSGL+ by Spinhaler
Number of subjects: 18
Study 6807149 — intervention group
Group type: EXPERIMENTAL
Intervention: DSGL- by Spinhaler
Number of subjects: 18
Study 6807149 — intervention group
Group type: EXPERIMENTAL
Intervention: DSGN nebulized solution
Number of subjects: 18
Study 6807149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29102588 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet of less fat and carbohydrates
Number of subjects: 62
Study 29102588 — intervention group
Group type: COMPARATOR
Intervention: No dietary limitations (Control group)
Number of subjects: 62
Study 30256894 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain-enriched diet
Number of subjects: 123
Study 30256894 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 123
Study 27402619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank‐ordered calorie labels plus a statement on energy needs per meal (CL)
Number of subjects: 372
Study 27402619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank‐ordered exercise labels showing minutes of brisk walking necessary to burn the food calories (EL)
Number of subjects: 372
Study 27402619 — intervention group
Group type: COMPARATOR
Intervention: Menus with no labels (NL)
Number of subjects: 372
Study 25119950 — intervention group
Group type: EXPERIMENTAL
Intervention: Varilrix(®) + cyclosporine (2.5 mg/kg/day)
Number of subjects: 24
Study 25119950 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous saline + cyclosporine (2.5 mg/kg/day)
Number of subjects: 24
Study 21127282 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 220
Study 21127282 — intervention group
Group type: COMPARATOR
Intervention: Midazolam infusion
Number of subjects: 220
Study 21127282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study 19643842 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing and Coordination (TC)
Number of subjects: 50
Study 19643842 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking, Endurance, Balance, and Strength (WEBS)
Number of subjects: 50
Study 17919215 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mL intradermal 1% lignocaine
Number of subjects: 300
Study 17919215 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl chloride
Number of subjects: 300
Study 17919215 — intervention group
Group type: EXPERIMENTAL
Intervention: entonox (50:50 oxygen : nitrous oxide)
Number of subjects: 300
Study 17919215 — intervention group
Group type: COMPARATOR
Intervention: no anaesthesia
Number of subjects: 300
Study 15449549 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide administration
Number of subjects: 20
Study 15449549 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study 11524188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy (n = 21 eyes)
Number of subjects: 25
Study 11524188 — intervention group
Group type: COMPARATOR
Intervention: No Vitrectomy (n = 20 eyes)
Number of subjects: 25
Study 9745451 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (MR antagonist)
Number of subjects: 0
Study 9745451 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (two doses)
Number of subjects: 0
Study 9745451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7836162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose solution containing 6‐[3H]glucose (CHO)
Number of subjects: 6
Study 2831524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (10 mg IV every six hours for three days, then 100 mg orally once a day for four days)
Number of subjects: 114
Study 2831524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114